Test my supply
+6 more ↓
69%
Finnrick rating
#205 of 301 ranked vendors
185 of 244 classifiable tests passed
methodology · Purity focus
Finnrick analysis

Reta-Peptide's purity-focused record is strongest on GHK-Cu and Tirzepatide, where broad, recent testing mostly supports identity, purity, and fill. The catalog is dispersed rather than uniform: CJC-1295 and BPC-157 have recent identity or 0 mg failures, and batch identifiers are inconsistent despite a current, high-volume evidence base.

methodology →
vendor intelligence report
Vendor Intelligence Report: Reta-Peptide

Corporate records and marketplace filings point away from the listed U.S. manufacturer story and toward a China-based trader model. The report maps the Retalux/@super_chem linkage, Shopify footprint, COA gaps, and crypto/wire payment rails.

27 pages6 risk factors assessed3 Jul 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.06
95%
27
2
Ipamorelin
$0.72
87%
15
3
Tirzepatide
$0.47
87%
36
4
Retatrutide
$1.00
85%
81
5
SS-31
$0.66
84%
4
6
PT-141
$0.60
69%
5
7
Melanotan II
$0.40
62%
5
8
Cagrilintide
$1.35
61%
4
9
BPC-157
$0.78
53%
17
10
Tesamorelin
$2.48
47%
18
11
MOTS-c
$0.57
43%
8
12
TB-500
$1.38
39%
12
13
CJC-1295
-
31%
9
14
NAD+
$0.01
29%
4
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%20 May 2026: 69%21 May 2026: 69%21 May 2026: 69%21 May 2026: 70%27 May 2026: 70%27 May 2026: 70%28 May 2026: 70%2 Jun 2026: 70%2 Jun 2026: 70%2 Jun 2026: 70%4 Jun 2026: 70%4 Jun 2026: 70%4 Jun 2026: 70%12 Jun 2026: 70%12 Jun 2026: 70%12 Jun 2026: 70%15 Jun 2026: 70%15 Jun 2026: 70%15 Jun 2026: 70%15 Jun 2026: 70%15 Jun 2026: 70%15 Jun 2026: 70%16 Jun 2026: 71%16 Jun 2026: 71%9 Jul 2026: 71%13 Jul 2026: 71%13 Jul 2026: 71%13 Jul 2026: 71%13 Jul 2026: 71%13 Jul 2026: 71%13 Jul 2026: 71%13 Jul 2026: 71%20 Jul 2026: 71%20 Jul 2026: 71%20 Jul 2026: 71%20 Jul 2026: 71%20 Jul 2026: 71%20 Jul 2026: 71%3 Aug 2026: 69%3 Aug 2026: 69%10 Aug 2026: current 69%69%70%69%May 26Aug 26
Test my supply
Reta-Peptide test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
3 Aug 2026Fail
NAD+
lab nameView COA
3 Aug 2026Fail
MOTS-c
lab nameView COA
20 Jul 2026Fail
Tesamorelin
lab nameView COA
20 Jul 2026Pass
Retatrutide
lab nameView COA
20 Jul 2026Fail
TB-500
lab nameView COA
20 Jul 2026Pass
Ipamorelin
lab nameView COA
20 Jul 2026Pass
GHK-Cu
lab nameView COA
20 Jul 2026Pass
MOTS-c
lab nameView COA
13 Jul 2026Pass
GHK-Cu
lab nameView COA
13 Jul 2026Pass
BPC-157
lab nameView COA
1-10 of 200

About Reta-Peptide test results from Finnrick

Reta-Peptide is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 14 peptides and 245 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Reta-Peptide peptides in this dataset are Melanotan II (5 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 200 recent tests.

Corrections
No corrections.
Test my supply